Header Bild flach farblich eingefärbtes Mikroskop

Fields of Funding

The BRIDGE 53 is open to projects with preliminary data sets targeting inter alia the following research activities in the area of human therapeutics development.

If you are interested in the BRIDGE 53 and have any further questions regarding the application process and fields of funding, please contact the program coordinator.

Wabenbild

TARGET VALIDATION

You have identified a target candidate for a novel anti-infective, but conclusive evidence that the target is related to the proposed mechanism-of-action is missing.

  • We will set up a project applying industry expertise in differential expression studies followed by bioinformatics-driven data mining and hypothesis building as well as in vitro and in vivo gene knock-out and over-expression studies - including CRISPR-Cas9 gene editing technologies - to validate your target candidate.

TESTING NOVEL THERAPEUTICS IN IN VITRO MODELS

You have developed a therapeutic antibody or small molecule against a first-in-class target to treat an infectious disease. Your antibody or compound has excellent on-target activity but its cellular effects in a physiological context are difficult to study.

  • We will assist you with setting up a project that characterizes the potency, selectivity and the functional effects of your molecule in relevant cellular environments and to perform the necessary translational studies by testing the proposed mechanism of your molecule using disease-relevant cellular systems.

TESTING NOVEL THERAPEUTICS IN IN VIVO MODELS

You have generated a candidate for a novel broad-spectrum antibiotic with break-through therapeutic potential.

  • We will support you with a project that comprises the identification of the most appropriate in vivo model(s) to interrogate pharmacodynamics effects and the therapeutic efficacy of your antibiotic candidate. All experimental procedures involving animals are carried out to the highest standards of animal welfare in state-of-the-art facilities and approved according to European Union and national regulations.

OPTIMIZING TOOL COMPOUNDS

You have studied a small molecule tool compound to treat bacterial, viral or parasitic infections – but the potency is too low for definitive conclusions on the MoA.

  • We will set up a project that brings to bear MedChem expertise to generate initial SAR (structure-activity relationship) and to inquire whether the tool compound can be optimized according to industry-best-practice.

FOR FURTHER INFORMATION

contact us